Open AccessLosartan and end‐organ protection—lessons from the renaal study
Author(s) -
Kowey Peter R.,
Dickson Tania Z.,
Zhang Zhongxin,
Shahinfar Shahnaz,
Brenner Barry M.
Publication year - 2005
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960280307
Subject(s) - medicine , losartan , proteinuria , myocardial infarction , stroke (engine) , diabetic nephropathy , nephropathy , diabetes mellitus , cardiology , type 2 diabetes , angiotensin ii , blood pressure , endocrinology , kidney , mechanical engineering , engineering
Background: The Reduction in ENdpoints with the Angiotensin Antagonist Losartan (RENAAL) study reported that losartan delayed the progression of renal disease in patients with type 2 diabetes and nephropathy. Diabetic or renally impaired patients are at high cardiovascular risk, a risk potentially increased in patients with both conditions. Hypothesis: This post hoc analysis examined whether baseline proteinuria was predictive of cardiovascular outcomes, and whether losartan modifies the risk of cardiovascular outcomes in these patients given its renal‐protective effects. Methods: The RENAAL study compared losartan with placebo (in addition to conventional antihypertensive medications) in type 2 diabetic patients with proteinuria. Morbidity and mortality due to cardiovascular causes were ascertained, and the relationship between baseline proteinuria and cardiovascular outcome was determined. The effect of treatment with losartan was examined using three time‐to‐event analyses of composite cardiorenal outcomes as described below. Results: Increasing baseline proteinuria was associated with significantly increased risk of myocardial infarction (MI) and all‐cause or cardiovascular death, but not stroke. Losartan significantly reduced the risk for the combined endpoint of end‐stage renal disease (ESRD), MI, stroke, or death by 21% (p ≤ 0.005), irrespective of whether all‐cause or cardiovascular death was included in the analysis. In addition, losartan reduced the risk for the composite of ESRD or cardiovascular death by 19.2% (p < 0.05). Conclusion: In patients with type 2 diabetes and nephropathy, there is an increased risk of MI and cardiovascular or all‐cause mortality. Treatment with losartan is associated with a reduction in proteinuria, a delay in the onset of ESRD, and no increased risk of cardiovascular events in this pre‐ESRD population.